Dabur India has signed a licence pact with the government to produce two new ayurvedic drugs -- Ayush - 64 for treatment of malaria and Ayush- 82 for management of diabetes. The company is planning to commercially produce the two drugs within six months and they will be available in various formats.
The company has also signed a memorandum of understanding (MoU) with the Central Council of Research in Ayurvedic Sciences (CCRAS), an apex research body under the Ministry of AYUSH, for collaboration and cooperation in the pharmaceutical R&D for different novel dosage forms and drug development in ayurveda. The ayurvedic formulations for both medicines were developed by CCRAS.
Dabur India is one of the largest FMCG Company in India. Building on a legacy of quality and experience of over 125 years, Dabur operates in key consumer products categories like Hair Care, Oral Care, Health Care, Skin Care, Home Care & Foods.
| Company Name | CMP |
|---|---|
| Hindustan Unilever | 2287.90 |
| Godrej Consumer Prod | 1042.50 |
| Dabur India | 487.60 |
| Colgate Palmol. (I) | 2196.75 |
| P&G Hygiene | 9930.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: